Evidence map›Paper›PMID 41681711›Full record

ReviewDiagnostics (Basel, Switzerland)2026

The Central Role of Oxidative Stress in Diabetic Retinopathy: Advances in Pathogenesis, Diagnosis, and Therapy.

Nicolas Tuli, Harry Moroz, Armaan Jaffer, Merve Kulbay, Stuti M Tanya, Feyza Sule Aslan, Derman Ozdemir, Shigufa Kahn Ali, Cynthia X Qian

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicolas TuliFaculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada.
Harry MorozFaculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada.ORCID 0009-0009-8178-5615
Armaan JafferFaculty of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0009-0008-0953-8487
Merve KulbayDepartment of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 3S5, Canada.ORCID 0000-0003-2756-3973
Stuti M TanyaDepartment of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 3S5, Canada.ORCID 0000-0003-1190-7129
Feyza Sule AslanFaculty of Medicine, Marmara University, 34722 Istanbul, Turkey.ORCID 0000-0002-0898-3334
Derman OzdemirInternal Medicine/Critical Care, Eastern New Mexico Medical Center, Roswell, NM 88201, USA.ORCID 0009-0000-0523-2394
Shigufa Kahn AliCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC H1T 2M4, Canada.
Cynthia X QianCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC H1T 2M4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR) remains the leading cause of preventable blindness among working-age adults worldwide, driven by the growing prevalence of diabetes mellitus. The aim of this comprehensive literature review is to provide an insightful analysis of recent advances in the pathogenesis of DR, followed by a summary of emerging technologies for its diagnosis and treatment. Recent studies have explored the roles of cell death pathways, immune activation, and lipid peroxidation in the pathology of DR. However, at the core of DR pathology lies neovascularization driven by vascular endothelial growth factor (VEGF), and mitochondrial damage due to dysregulated oxidative stress. These dysregulated pathways manifest clinically as DR, with specific subtypes including non-proliferative DR, proliferative DR and diabetic macular edema, which can be diagnosed through various imaging modalities. Recently, novel advances have been made using liquid biopsy and artificial (AI)-based algorithms with the goal of transforming DR diagnostics. AI models show distinct promise with the capacity to provide automated interpretation of retinal imaging. Furthermore, conventional anti-VEGF injectable agents have revolutionized DR treatment in the past decades. Today, as the pathogenesis of DR becomes better understood, new pathways, such as the ROS-VEGF loop, are being elucidated in greater depth, enabling the development of targeted therapies. In addition, new innovations such as intravitreal implants are transforming the delivery of DR-specific medication. This paper will discuss the current understanding of the pathogenesis of DR, which is leading to new diagnostic and therapeutic tools that will transform clinical management of DR.

Indexed as

diabetic macular edemadiabetic retinopathymitochondrial dysfunctionneovascularizationoxidative stress

Identifiers

PMID41681711
PMCPMC12896838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.